Ignite Creation Date:
2025-12-24 @ 3:51 PM
Ignite Modification Date:
2026-01-01 @ 7:19 AM
Study NCT ID:
NCT01133392
Status:
COMPLETED
Last Update Posted:
2014-12-30
First Post:
2010-05-27
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Bioequivalence of Two Lispro Formulations
Sponsor:
Eli Lilly and Company
Organization:
Study Overview
Official Title:
Evaluation of the Bioequivalence of Two Formulations of Insulin Lispro in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will compare how the body treats 2 different forms of insulin lispro and how they affect blood sugar levels.
Detailed Description:
The 2 formulations of insulin lispro will be referred to here as:
Lispro A
Lispro B
Lispro A
Lispro B
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| F3Z-EW-IOPY | OTHER | Eli Lilly and Company | View |